Drug developers aim to treat cystic fibrosis through disease modification.
Thompson
Cheryl A
CA
D000280:Administration, Inhalation; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000096:biosynthesis / Q000235:genetics*; D003845:Deoxycytosine Nucleotides / Q000627:therapeutic use*; D015316:Genetic Therapy; D006801:Humans; D009154:Mutation; D010069:Oxadiazoles / Q000627:therapeutic use*; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; D014529:Uridine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003845:Deoxycytosine Nucleotides; D010069:Oxadiazoles; C546385:P2RY2 protein, human; D058910:Purinergic P2 Receptor Agonists; D058473:Receptors, Purinergic P2Y2; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C465279:denufosol tetrasodium; C515878:ataluren; D014529:Uridine